Dr. Voorhees on the Role of CAR T-Cell Therapy in Multiple Myeloma

Video

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Peter Voorhees, MD, physician, Levine Cancer Institute, Atrium Health, discusses the role of CAR T-cell therapy in multiple myeloma.

BCMA-targeted CAR T-cell therapies have shown unprecedented response rates and depth of response in patients with heavily pretreated relapsed/refractory multiple myeloma, says Voorhees.

Unlike B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma, CAR T-cell therapy has not shown curative potential in multiple myeloma, says Voorhees.

The investigational CAR T-cell therapy, bb2121 (idecabtagene vicleucel), demonstrated a median progression-free survival (PFS) of 11.8 months (95% CI, 6.2-17.8) in patients with heavily pretreated relapsed/refractory disease in the phase I CRB-401 study (NCT02658929). Though patients will progress on this treatment, 1-year PFS in this setting is highly encouraging, explains Voorhees.

Moving CAR T-cell therapy into earlier lines of treatment may elicit more durable responses, says Voorhees. Additionally, CAR T-cell therapy may have the potential to overcome high-risk disease in patients who do not respond well to initial therapy, or in those who relapse after frontline treatment, concludes Voorhees.

Related Videos
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
© 2024 MJH Life Sciences

All rights reserved.